GSA Capital Partners LLP Takes $901,000 Position in Omnicell, Inc. (NASDAQ:OMCL)

Key Points

• GSA Capital Partners LLP acquired a new position in Omnicell, Inc. (NASDAQ:OMCL) by purchasing 25,781 shares valued at approximately $901,000.
• Analysts are optimistic about Omnicell's prospects, with the stock receiving upgrades to a "strong-buy" rating and an average target price of $45.33.
• Omnicell reported earnings of $0.45 per share for the last quarter, surpassing estimates and showing a 5.0% increase in revenue year-over-year.

GSA Capital Partners LLP bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,781 shares of the company's stock, valued at approximately $901,000. GSA Capital Partners LLP owned approximately 0.06% of Omnicell as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Omnicell by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock valued at $247,628,000 after purchasing an additional 28,573 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Omnicell by 10.1% in the 1st quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock valued at $58,745,000 after purchasing an additional 154,038 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after acquiring an additional 394,820 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Omnicell by 81.6% in the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after acquiring an additional 737,536 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in shares of Omnicell by 4.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock worth $53,290,000 after acquiring an additional 56,117 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Stock Up 4.3%

Shares of NASDAQ OMCL traded up $1.27 during mid-day trading on Monday, reaching $31.03. The company had a trading volume of 138,396 shares, compared to its average volume of 565,326. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The firm has a 50 day simple moving average of $29.27 and a two-hundred day simple moving average of $33.05. The stock has a market cap of $1.45 billion, a P/E ratio of 62.05, a PEG ratio of 8.69 and a beta of 0.78. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same quarter in the prior year, the business earned $0.51 EPS. Omnicell's quarterly revenue was up 5.0% compared to the same quarter last year. Sell-side analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OMCL. Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Benchmark cut their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen raised shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Bank of America increased their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Finally, Wells Fargo & Company increased their price objective on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.